ArticleCureus2026
Association of Increased MIEN1 Copy Number With Worse Outcomes in Lung Adenocarcinoma and Cervical Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma is the most common subtype of lung cancer and a significant contributor to cancer mortality globally. This has driven the development of targeted therapies, particularly those aimed at genetic alterations in certain genes, such as EGFR and ALK. ERBB2 (HER2) has also emerged as a potential oncogenic driver and therapeutic target in lung adenocarcinoma. Notably, ERBB2 is in close proximity on chromosome 17 to GRB7 and MIEN1, which are potential contributors to invasion and metastasis. Using TCGA-LUAD (The Cancer Genome Atlas Lung Adenocarcinoma) and CPTAC-3 (Phase III of the Clinical Proteomic Tumor Analysis Consortium) lung adenocarcinoma datasets, copy number variations (CNVs) for GRB7, ERBB2, and MIEN1 and their associations with various survival parameters were obtained. Results indicated that increased copy number (CN) of MIEN1 was significantly associated with worse disease-free survival (DFS) in both TCGA-LUAD and CPTAC-3 lung adenocarcinoma datasets and was significantly associated with worse progression-free survival (PFS) in the TCGA-LUAD dataset. There is also evidence showing a similar relationship in cervical cancer, which also has established links to ERBB2. CNV analyses in the TCGA-CESC and CGCI-HTMCP-CC (Cancer Genome Characterization Initiative-HIV+ Tumor Molecular Characterization Project-Cervical Cancer) cervical cancer datasets revealed that only increased CN of MIEN1 was statistically significantly associated with worse overall survival (OS) in both datasets. These CNV analyses suggest that MIEN1 should be further investigated as a potential contributor to oncogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.